Katowice, Poland - May 28, 2025, AnchorMan^® Left Atrial Appendage Closure (AnchorMan^®), independently developed by Shanghai MicroPort CardioAdvent Co., Ltd (MicroPort CardioAdvent), a subsidiary of MicroPort CardioFlow Medtech Corporation (CardioFlow, 02160.HK), successfully completed its first post-market clinical application overseas at the prestigious Medical University of Silesia in Katowice, Poland, marking a significant breakthrough in its global expansion.

The Medical University of Silesia is a leading public medical center in Poland with an authoritative reputation in the field of cardiovascular treatment. The procedure was performed by a team led by Dr. Wojtek Wojakowski, Director of the Department of Cardiology and Structural Heart Diseases. Postoperatively, the patient's left atrial appendage closure remained stable with no complications, achieving a complete success.

Case Details

01 Preoperative Assessment

The patient was a 76-year-old male with paroxysmal atrial fibrillation who experienced two episodes of major urethral bleeding after oral anticoagulation therapy. His medical history included myocardial infarction, diabetes, and post-prostatectomy. With a CHA2DS2-VASc score of 4 and a HAS-BLED score of 3, the patient was at high risk of stroke. TEE and CTA revealed no thrombus in the left atrium or left atrial appendage.

02 CT Analysis Summary and Surgical Strategy

The patient's LAA exhibited anti-chicken wing type with a low position. The LAA measured 20-24mm in orifice diameter, with a middle lobe depth of 19-20mm and anti-chicken wing lobe depth of 23mm.

The preliminary surgical strategy was as follows:

a) Due to the low position and anti-chicken wing type of the LAA, The location for the atrial septal puncture was selected as inferior (inferior/superior) and middle (anterior/posterior) .

b) During DSA angiography, the conventional RAO30 CAU20 projection obscured the lower edge of the LAA, so an RAO30 CAU10 projection was advised.

c) Given the difficulty in achieving optimal axial alignment with the reverse chicken-wing lobe, occlusion targeting the middle lobe was considered.

Surgical Outcomes

The left atrial appendage closure was implanted in an optimal position, demonstrating stable traction, a compression ratio of 13.8%–17.2%, no residual diversion, and no complications.

Surgical Evaluation

Dr. Wojtek Wojakowski

Postoperatively, Dr. Wojtek Wojakowski highly praised the clinical performance of AnchorMan^®, noting its short learning curve and intuitive operability. He particularly highlighted its unique 3D folded distal rounded design, which significantly enhanced procedural safety and ease of use. He also remarked that the product's quality and performance met international advanced standards and expressed optimism that it would provide Polish patients with superior treatment options.

Message from CardioFlow Management

Mr. Zhang Ruinian, President

As the only left atrial appendage closure system in China to receive dual certification from both China and Europe, AnchorMan^® achieved a milestone of 500 implants within just one year of its launch in the Chinese market, with zero cases of serious complications and a 100% success rate, earning high recognition from leading experts and atrial fibrillation patients. Now, AnchorMan^® is making its global debut with its innovative semi-occlusive plug design and outstanding clinical performance following its CE MDR certification in February 2025, marking the official launch of its global journey and showcasing the innovation and competitiveness of "Intelligent Manufacturing in China" to the world.

Mr. Chen Guoming, Chairman

Over the past year, two of CardioFlow's innovative products—the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System and AnchorMan^® Left Atrial Appendage Closure—have successively obtained the stringent CE MDR certification, gaining entry into leading European hospitals and rapidly achieving clinical application. These milestones not only demonstrate the company's innovative capabilities in the field of structural heart disease treatment, enabling it to compete with global leaders and expand into more overseas markets, but also highlight the strong synergy between the two flagship products. This synergy will further deepen the company's penetration in international markets, significantly enhance financial performance, and drive high-quality development while benefiting more global patients with structural heart disease.